Compare CDIO & JTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CDIO | JTAI |
|---|---|---|
| Founded | 2017 | 2018 |
| Country | United States | United States |
| Employees | 17 | 9 |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7M | 11.1M |
| IPO Year | N/A | N/A |
| Metric | CDIO | JTAI |
|---|---|---|
| Price | $2.03 | $6.96 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $80.00 |
| AVG Volume (30 Days) | 56.4K | ★ 183.3K |
| Earning Date | 05-13-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $171,906.75 | N/A |
| Revenue Next Year | N/A | $0.73 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.97 | $0.04 |
| 52 Week High | $7.91 | $10.41 |
| Indicator | CDIO | JTAI |
|---|---|---|
| Relative Strength Index (RSI) | 54.21 | 47.24 |
| Support Level | $1.68 | $5.96 |
| Resistance Level | $2.13 | $7.79 |
| Average True Range (ATR) | 0.17 | 0.67 |
| MACD | 0.01 | -0.15 |
| Stochastic Oscillator | 43.02 | 35.89 |
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases and associated comorbidities by leveraging its Artificial Intelligence (AI)-driven Multi-Omics Engine. The company has developed two clinical products: Epi+Gen CHD and PrecisionCHD, epigenetics-based clinical blood tests capable of assessing risk for a coronary heart disease (CHD) event, including heart attacks. Additionally, its portfolio includes HeartRisk, a cardiovascular disease risk intelligence platform, and CardioInnovate360, a research-use-only solution launched to support the discovery, development, and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases.
Jet AI Inc is principally involved in the sale of fractional and whole interests in aircraft, the sale of jet cards, which enable holders to use certain of the company's and other's aircraft at agreed-upon rates, the operation of a proprietary booking platform, which functions as a prospecting and quoting platform to arrange private jet travel with third-party carriers as well as via the company's leased and managed aircraft, direct chartering of its HondaJet Elite aircraft by Cirrus Aviation Services, aircraft brokerage and monthly management and hourly operation of customer aircraft. It also offers the SaaS software to aircraft owners and operators generally: Reroute AI; and DynoFlight. The company operates in a single operating and reportable segment which is private aviation services.